Lexicon Pharmaceuticals | LXRX - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Abbott USD 52.13B 1.3B 2025-12
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Agios Pharmaceuticals USD 1.19B 91.22M 2025-12
Akebia Therapeutics USD 32.61M 8.98M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
AstraZeneca USD 48.67B 2.78B 2025-12
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Esperion Therapeutics USD -301.96M 149.4M 2025-12
Halozyme Therapeutics USD 48.81M 455.1M 2025-12
Illumina USD 2.72B 342M 2025-12
Insmed USD 738.98M 206.6M 2025-12
Ironwood Pharmaceuticals USD -264.16M 44M 2025-09
J&J USD 78.47B 0 2025-09
Lexicon Pharmaceuticals USD 107.54M 12.62M 2025-12
MacroGenics USD 55.59M 11.41M 2025-12
MannKind USD -51.02M 6.47M 2025-12
Merck USD 51.85B 2.79B 2025-09
Moderna USD 8.65B 680M 2025-12
Novartis USD 46.13B 1.38B 2025-12
PTC Therapeutics USD -205.31M 49.56M 2025-12
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Thermo Fisher Scientific USD 53.54B 2.38B 2025-12
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
United Therapeutics USD 7.1B 506M 2025-12
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12